Mois : septembre 2019

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome, Blathnaid McCoy et al., 2018

A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III Annals of Clinical and Translational Neurology, 2018, 5, (9), 1077–1088 doi: 10.1002/acn3.621   Abstract Introduction : Both D9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug-resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary [...]

Lire la suite

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome, Bin GU et al., 2019 model mice,

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]

Lire la suite

IACM-Bulletin du 27 Septembre 2019

IACM-Bulletin du 27 Septembre 2019 Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Science/Homme: La capsaïcine peut être utile dans le syndrome d'hyperémèse de cannabinoïde Science/Homme: Le THC peut être utile chez les patients souffrant de douleur gériatrique En bref Un coup d'œil sur le passé Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Lors d’une étude portant sur 59 824 patients, la consommation de cannabis [...]

Lire la suite

EC Clears Cannabidiol for Severe Forms of Epilepsy – Medscape -Deborah Brauser,  Sep 23, 2019.

EC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019   The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]

Lire la suite

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017, Hongying Dai & Kimber P. Richter, 2019

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017 Hongying Dai, Kimber P. Richter JAMA Network Open, 2019, 2, (9), e1911936. doi:10.1001/jamanetworkopen.2019.11936   Abstract IMPORTANCE : The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES : To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by sociodemographic group, and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN, SETTING, AND PARTICIPANTS : This survey study used a probability [...]

Lire la suite

Textes – Recueil du Bon Plant, François Olivier Gagnon-Hébert, 2019

Textes - Recueil du Bon Plant François Olivier Gagnon-Hébert 2019   Titre : Pas de panique ! Le cannabis était là avant nous… et il le sera sûrement encore après nous.   Le cannabis, ce n’est pas le nom d’un poison, ni d’une drogue pharmaceutique. Ce n’est pas non plus un mot inventé par les politiciens pour faire peur ou pour influencer les résultats d’un concours de popularité à l’échelle du pays. Le cannabis peut être bien des choses pour bien des personnes, mais avant même d’être le démon incarné qui rend les mœurs légères, et avant même d’être le prochain remède holistique à tous les maux [...]

Lire la suite

Adolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus, Grace Blest‐Hopley et al., 2019

Adolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus Grace Blest‐Hopley | Aisling O'Neill | Robin Wilson | Vincent Giampietro | David Lythgoe | Alice Egerton | Sagnik Bhattacharyya Addiction Biology, 2019, e12827, 1-11. DOI: 10.1111/adb.12827   Abstract Cannabis use has been associated with adverse mental health outcomes, the neurochemical underpinnings of which are poorly understood. Although preclinical evidence suggests glutamatergic dysfunction following cannabis exposure in several brain regions including the hippocampus, evidence from human studies have been inconsistent. We investigated the effect of persistent cannabis use on the brain levels of N‐acetyl aspartate (NAA) and myo-inositol, [...]

Lire la suite

The genus Datura L. (Solanaceae) in Mexico and Spain – Ethnobotanical perspective at the interface of medical and illicit uses, Guillermo Benítez et al., 2018

The genus Datura L. (Solanaceae) in Mexico and Spain – Ethnobotanical perspective at the interface of medical and illicit uses Guillermo Benítez, Martí March-Salas, Alberto Villa-Kamel, Ulises Cháves-Jiménez, Javier Hernández, Nuria Montes-Osuna, Joaquín Moreno-Chocano, Paloma Cariñanos Journal of Ethnopharmacology, 2018, Volume 219, Pages 133-151. https://doi.org/10.1016/j.jep.2018.03.007   A B S T R A C T Ethnopharmacological relevance : The different species of the genus Datura have been used traditionally by some pre-Columbian civilizations, as well as in medieval rituals linked to magic and witchcraft in both Mexico and Europe. It is also noteworthy the use of different alkaloids obtained from the plants for medicinal purposes in the treatment [...]

Lire la suite

The Consumption of Psychoactive Plants During Religious Rituals : The Roots of Common Symbols and Figures in Religions and Myths, H. Umit Sayin, 2014

The Consumption of Psychoactive Plants During Religious Rituals : The Roots of Common Symbols and Figures in Religions and Myths H. Umit Sayin NeuroQuantology, June 2014, Volume 12, Issue 2, 276-296 Doi : 10.14704/nq.2014.12.2.753   ABSTRACT Psychoactive plants which contain hallucinogenic molecules that induce a form of altered states of consciousness (HASC) have been widely used during the religious rituals of many cultures throughout the centuries, while the consumption of these plants for spiritual and religious purposes is as old as human history. Some of those cultures were shaman and pagan subcultures; African native religions; Bwiti Cult; South American native religions; Amazon Cultures; Central American Cultures; [...]

Lire la suite